FINWIRES · TerminalLIVE
FINWIRES

調査速報:ハッベル社:公益事業/データセンターインフラ需要により第1四半期の業績が押し上げられる

By

-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。HUBBは、第1四半期のEPSが前年同期比16%増の3.93ドルと好調な業績を記録し、市場予想の3.86ドルを上回りました。売上高は11%増の16億ドルとなり、データセンターおよび公益事業インフラへの投資加速による8.2%の堅調なオーガニック成長が牽引しました。この好業績は、電力網の近代化投資と、データセンターにおける電気製品需要の継続によってもたらされました。経営陣は2026年の業績見通しを引き上げ、売上高全体の成長率を8%~11%(うちオーガニック成長率6%~9%)と予想し、調整後EPSを19.30ドル~19.85ドルに引き上げました。公益事業ソリューションは、送電網インフラが電力会社による送電および変電所インフラへの投資により約18%の大幅な拡大を遂げたことが牽引し、11%増の9億4,900万ドルとなりました。一方、電気ソリューションは、データセンター事業の好調が継続したことで12%増の5億6,800万ドルとなりました。調整後営業利益率は110ベーシスポイント拡大し19.8%となり、公益事業ソリューションの利益率は販売量増加と価格戦略により190ベーシスポイント急上昇して21.8%となりましたが、電気ソリューションの利益率はコスト圧力とリストラ投資により30ベーシスポイント縮小して16.4%となりました。

Related Articles

Research

Research Alert: Bio: Q1 Results Above Estimates Despite Meaningful Sales/margin Compression

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:BIO delivered Q1 results showing pressure across both segments, with revenue of $592.1M growing 1.1% Y/Y (~$3M above consensus) but declining 4.2% currency neutral. Adjusted EPS of $1.89 fell 25.6% Y/Y yet beat consensus by $0.10, while operating margin deteriorated 420 bps to 6.6% from 10.8% in the prior year. Both Life Science and Clinical Diagnostics segments experienced currency neutral declines due to ongoing academia weakness and Middle East conflicts. Management lowered 2026 guidance, expecting currency neutral revenue of -3.0% to +0.5% growth (down from +0.5% to +1.5%) and operating margin of 10.0%-12.0% (vs. prior 12.0%-12.5%). Despite operational headwinds, BIO maintained strong cash generation with $78.1M in FCF and repurchased ~176K shares. The company's balance sheet remains healthy, with $1.56B in cash and short-term investments, providing financial flexibility amid challenging market conditions, in our view.

$BIO
Asia

ResMed Posts Higher Fiscal Q3 Non-GAAP Earnings, Revenue

ResMed (ASX:RMD) reported Friday fiscal third-quarter non-GAAP earnings of $2.86 per share, up from $2.37 a year earlier.Analysts polled by FactSet expected earnings of $2.80.Revenue for the three months ended March 31 was $1.43 billion, compared with $1.29 billion a year earlier. Analysts surveyed by FactSet expected $1.42 billion.The company expects its fiscal 2026 non-GAAP gross margin to be between 62% and 63%.The board declared a quarterly dividend of $0.60 per share, up from $0.53 a year earlier, payable June 18 to shareholders on record as of May 14.

$ASX:RMD
Research

Research Alert: Gddy: Strong Profitability Metrics Offset By Continued Revenue Headwinds

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:GDDY posted Q1 2026 revenue of $1.2B (+6%), in line with consensus, with EPS of $1.60 beating estimates of $1.52 despite booking deceleration to +2.7% from +5% in Q4. A&C segment growth of +11.6% to $498M showed resilience but continued moderating, while Core Platform remained sluggish at +2.8%. We view booking weakness as concerning given competitive pressures and small business spending constraints that raise questions about growth sustainability. Management reaffirmed 2026 revenue guidance of $5.195B-$5.275B (~6% growth), reflecting limited visibility into booking improvement. However, we see encouraging AI monetization signs with ARPU growth of +9.3% to $246 and Airo AI Builder achieving multi-million dollar annualized bookings within weeks of beta launch. We believe GDDY's impressive margin expansion with NEBITDA margins reaching 32.6% (+210 bps) demonstrates operational discipline, though sustaining A&C growth above 10% remains critical for investor confidence.

$GDDY